GSK still doing more than peers for the poor, says study

20 November 2018

GlaxoSmithKline (LSE: GSK) remains the Robin Hood of pharma when it comes to providing medicines to the world’s poorest people.

The UK drugmaker has retained its position at the top of the Access to Medicine Index, an independent ranking of 20 of the leading pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries.

Swiss pharma giant Novartis (NOVN: VX) moves into second, ahead of Johnson & Johnson (NYSE: JNJ) and Merck KGaA (MRK: DE), with Japanese drugmaker Takeda (TYO: 4502) jumping up 10 places from its ranking in 2016 and completing the top five.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK